Peer Review History

Original SubmissionMay 28, 2025
Decision Letter - Hong Qin, Editor

PONE-D-25-24494Leveraging Dynamic Stability to Infer Regulation in Protein-Protein Interaction Networks: A Study of Infectious Vulnerability in COPD.PLOS ONE

Dear Dr. Broderick,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 29 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Hong Qin, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

3. Thank you for stating the following financial disclosure:

“FUNDING

This work was supported by Rochester Regional Health (G. Broderick) in conjunction with the US Department of Defense Congressionally Directed Medical Research Programs (CDMRP) under Peer Reviewed Medical Research Program (PRMRP) award W81XWH1910804 (Broderick - PI; Sethi - Partnering PI). VIDO receives operational funding from the Canada Foundation for Innovation through the Major Science Initiatives Fund and from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture (G. Broderick).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information .

7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. This manuscript presents a novel computational approach to infer directed regulatory relationships from undirected protein-protein interaction networks using cross-sectional data from COPD patients. The work addresses an important clinical problem and introduces an innovative methodological framework. From informatics point of view, I believe this is an important work in network biology field and have shown potentially a new method of analysis this type of data.

2. However, as a reader who is interested in implementing this pipeline, I would suggest all the codes and data be made available in accordance to the open science standard. The current methods section describes the fundamental of the method but lacking the implementation or codes related to the implementation. The codes can be made available in a GitHub repository.

3. Apart from that, are the data for the LC-MS available in a database? The link to the data should be made available.

4. The availability of the entire pipeline and use case data is important in order for this analysis to be implemented on other datasets from different diseases.

Reviewer #2: Here are my comments:

1. The experiments appear to have been conducted exclusively on male subjects. This raises concerns about potential gender bias in the results. Including female subjects would have strengthened the study by improving the generalizability and robustness of the findings

2. In Figure 7, the gene network visualization displays various connections or interactions among genes. However, the meaning of the different edge colors is not explained. Additionally, are there certain genes within the network that play a more central or influential role? Clarifying these aspects would provide greater biological insight into the findings.

3. It would enhance the paper if the authors compared their proposed method against other established approaches, such as those referenced in [3, 4]. A comparative analysis would better highlight the strengths and potential limitations of the proposed method.

4. All figures should be positioned close to their corresponding references in the main text. As currently presented, it is difficult to follow the narrative without frequently scrolling between the text and the figures. This disrupts the flow of reading and makes it harder to interpret the results effectively.

5. Several figures, particularly Figure 3, lack a proper legend. Including clear legends is essential for readers to understand the plotted information without ambiguity.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1:

1. This manuscript presents a novel computational approach to infer directed regulatory relationships from undirected protein-protein interaction networks using cross-sectional data from COPD patients. The work addresses an important clinical problem and introduces an innovative methodological framework. From informatics point of view, I believe this is an important work in network biology field and have shown potentially a new method of analysis this type of data.

Ans.

Sincere thanks for the kind words.

2. However, as a reader who is interested in implementing this pipeline, I would suggest all the codes and data be made available in accordance to the open science standard. The current methods section describes the fundamental of the method but lacking the implementation or codes related to the implementation. The codes can be made available in a GitHub repository.

Ans.

We very much agree and apologize for this omission. We have now added as new supplementary material the Python source code ( COPD_cpmpy_param_est_from_list.py) that will read a sample input file (COPD_Serum_15_PPI_input.xlsx) and produce a set of competing solutions consisting of directed networks with corresponding logic parameter values. We now point to these files in the Methods section. All such changes to the main text have been highlighted in blue font for the convenience of the reviewer.

3. Apart from that, are the data for the LC-MS available in a database? The link to the data should be made available.

Ans.

Again, sincere apologies for this oversight. We have now also provided as supplementary material the original LC-MS data (COPD-proteomics_serum_original_data.xlsx).

4. The availability of the entire pipeline and use case data is important in order for this analysis to be implemented on other datasets from different diseases.

Ans.

We agree with the reviewer and have amended the main text pointing to these new supplementary files. All such changes to the text have been highlighted in blue font for the convenience of the reviewer.

Reviewer #2: Here are my comments:

1. The experiments appear to have been conducted exclusively on male subjects. This raises concerns about potential gender bias in the results. Including female subjects would have strengthened the study by improving the generalizability and robustness of the findings.

Ans.

We agree with the reviewer. Unfortunately, the scope of the current project as funded by the US DoD directed sex comparisons as part of a future phase of work. We have emphasized this limitation in the Discussion and highlighted changes to the text in blue font for the convenience of the reviewer.

2. In Figure 7, the gene network visualization displays various connections or interactions among genes. However, the meaning of the different edge colors is not explained. Additionally, are there certain genes within the network that play a more central or influential role? Clarifying these aspects would provide greater biological insight into the findings.

Ans.

While the color and type of interaction were described in the caption for Figure 7, we agree with the reviewer and have modified the main text to clarify this further. Regarding the relative importance of the genes in the representative model of Figure 7, we very much agree with the reviewer and appreciate the reviewer raising this point. We have now conducted a topological analysis of the network on Figure 7 and have include these results in the new Supplemental Table S7. It is interesting to note P01700 (IGLV1-47), a key factor in antibody antigen recognition [Huang et al., 2024], and P30046 (DDT), an inhibitor of macrophage migration [Merk et al., 2011], as having the highest and second highest betweenness centralities highlighting potential dysregulation in immune recognition and innate immune response as playing a key role in increased vulnerability to infection. We have inserted a new passage to this effect in Section 3.3 and to the Discussion.

Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, Fan J, Lue H, Chen Y, Xiong H, Chagnon F. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proceedings of the National Academy of Sciences. 2011 Aug 23;108(34):E577-85.

Huang X, Xiong L, Zhang Y, Peng X, Ba H, Yang P. Proteomic profile of the antibody diversity in circulating extracellular vesicles of lung adenocarcinoma. Scientific Reports. 2024 Nov 14;14(1):27953.

Again, all changes to the main text have been highlighted in blue font for the convenience of the reviewer.

3. It would enhance the paper if the authors compared their proposed method against other established approaches, such as those referenced in [3, 4]. A comparative analysis would better highlight the strengths and potential limitations of the proposed method.

Ans.

We very much appreciate this suggestion. The methods presented in references [3] and [4] consist in comparing two separate undirected graphs, each representing a different phenotype, and describing shifts in their structure or connectivity patterns. Our group has performed such analyses in the past (e.g. Broderick et al., 2010) and we could have identified separate graphs for the low and high exacerbation frequency phenotypes in this instance as well. However, the objective was to explore the feasibility of identifying a single regulatory network that would support both phenotypes as persistent or slowly progressing conditions. The existence of a single common network and regulatory program supporting both phenotypes implies that perturbation to this network exist that can redirect a network behavior from a high frequency response back to response patterns characteristic of a lower illness severity. We propose to the reviewer that this is significantly more challenging to articulate in terms of shifts in active interactions when working with separate often undirected interaction graphs. We have added a statement to this effect in the Discussion (please see insertions in blue font).

Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain, behavior, and immunity. 2010 Oct 1;24(7):1209-17.

4. All figures should be positioned close to their corresponding references in the main text. As currently presented, it is difficult to follow the narrative without frequently scrolling between the text and the figures. This disrupts the flow of reading and makes it harder to interpret the results effectively.

Ans.

We agree with the reviewer and apologize for the awkward generic format of the draft manuscript submission. It is our understanding that this will be addressed during typesetting should the manuscript be accepted for publication.

5. Several figures, particularly Figure 3, lack a proper legend. Including clear legends is essential for readers to understand the plotted information without ambiguity.

Ans.

We agree and have added additional explanations to the caption of Figure 3 as well as annotated the figure itself, now uploaded as Figure_3_r1. We apologize for this oversight and appreciate the reviewer’s patience.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Hong Qin, Editor

Leveraging Dynamic Stability to Infer Regulation in Protein-Protein Interaction Networks: A Study of Infectious Vulnerability in COPD.

PONE-D-25-24494R1

Dear Dr. Broderick,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hong Qin, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: My concerns have been addressed. The access to data and codes will help the field and allow other groups to replicate the work onto other datasets. Thank you.

Reviewer #2: The authors addressed all of my concerns I raised before. They did additional experiments and added new plots to answer my questions. They have used topological data analysis techniques to find out the important genes from a network. I want them to add the full description of the TDA technique they used in this version.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Hong Qin, Editor

PONE-D-25-24494R1

PLOS ONE

Dear Dr. Broderick,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hong Qin

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .